Solvd Health said the FDA approved its AvertD pharmacogenomic opioid use disorder test for blood-sample collection. The genotyping assay analyzes 15 genetic variants and extends beyond the earlier cheek-swab approval, aiming to make it easier for health systems to integrate genetic risk information into clinical workflows.